{"name":"GI Cell, Inc.","slug":"gi-cell-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GIC-102","genericName":"GIC-102","slug":"gic-102","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"GIC-102","genericName":"GIC-102","slug":"gic-102","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSnNidnpMbUxNWnRoczBlb09leUxvMXlFeWE3VjV6S3BZTFA3c0VRM0ViSTRvVHFSRDhzVkJNTEZkWV81MW9udzBoU3g1NlYycDJrdGhNTjJ0R3hVWWdCNmQ5UHptQ3R1SVdmR19IcWNmNW9HQXQ2ZFAwMHp0cW9udkZxNW5YTXlyTXp3ZnBNYVJOZFM1dkJLc3ZTRXpmd0h5bEVQa1hscVJhN09vN3ZTdmxrcjYySjE3R2FR?oc=5","date":"2026-02-26","type":"deal","source":"businessweekly.co.uk","summary":"Charles River Laboratories to divest a number of assets to IQVIA and GI Partners - businessweekly.co.uk","headline":"Charles River Laboratories to divest a number of assets to IQVIA and GI Partners","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOd1g1MVhubjFYSkpwaEZfZ1kxdm5lMVIwS0dzanBJR09PelBHc2V1YTVlV3RrejYtMXVBM1h5b2pGdFZOUWdXUmYzcTROVHdRQS03ejZqazcxZnFnam9HZko0UWJRbFpIYlFPSGVoNldkaENOT2FCUEZYSlpvdFZVM0J3TjJuVk9lRkZmMXZmQ25lbzZTNEJlS2xDOVdmZmwtalBBcnEwb05LSUJ4MTdMMWdJRUgyVEZOX0Q5NzFpbE8?oc=5","date":"2026-02-25","type":"pipeline","source":"Business Wire","summary":"Charles River Laboratories Provides Update on Planned Divestitures - Business Wire","headline":"Charles River Laboratories Provides Update on Planned Divestitures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPZ2RPUzNxRmhzM1ViNDMwaF9CenNrZ2RTTHVlbV95c0wwRV83dFJOVGVZY3VPeFBfSmJpS2JkRjlIcFI4NlJhWDVmYy1PWEVwQll3cExKYkdwOGRWaUFyS0pwaVVKSVNOTVd0OVozdkhabTlSSi1BNzhwa0VVYU4xSFJOampaMFJfZjZuYzlhZk1oMXA2VEpySkJZcU1fWThVYnh4MlFKMDhRZ3JpMUhLZlFhcE1IcUR2cVdaWXVFTE1PX3RxTUN4ZE81SFhKbFZSN1lBR0NCUWtLcHc?oc=5","date":"2026-02-25","type":"earnings","source":"reuters.com","summary":"Charles River raises annual profit view as it sells underperforming assets - reuters.com","headline":"Charles River raises annual profit view as it sells underperforming assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOVndOMExmSGJ3elprSUpRNjRyQzJtaG5sQWNSa0NrZFNEYTNxMUlVeVNfLThXaFlaNGd1MzV1VDI5dTBycF9MeC1XNHFnVl9Nb2h1bHk5UU1xamxXdGNXaUxLaDIxck9QdW5SbVlwY1czbHRJT0h3LXRyWUlmSVBpa0FGWkFFZENLaVBFTlhpaHlxbUNnT2taeXBhY1FicjdHemNqSk91QXBNRnBwNGp4X2JndTFsNmZKOGt5MXJR?oc=5","date":"2026-02-19","type":"trial","source":"BioSpace","summary":"Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - BioSpace","headline":"Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNM3dsaVhYY0Z4M0dUMDdCVzV0SFBCN0JXa19ibUxKd3hVNGsteUQ0d2s1cWJfZ0p5VG1kY0taZGZoMXdGY1E3cEp6cGo5VFZ4Z3BjVTY3VkFPWUZ2YlZ1bVNaemRBUk8taU8ydHZ2Tm9ZUlNxOElGVXV3UVowNnpHQ0xpcXRjZw?oc=5","date":"2025-11-17","type":"pipeline","source":"Yahoo Finance","summary":"Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - Yahoo Finance","headline":"Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Sig","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBtMzNaWGVCeUxlTk5zWDBNZW5fS2tBVWV6MDluc3F5bVoxeVVEX1VjWEh1dWFaWmExWDZ3TG10UXJXN0paaUdaME0yTEhrUS1qZHVOQ0NHSVJ5Q0p4T3JF?oc=5","date":"2025-11-04","type":"trial","source":"nature.com","summary":"Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research - na","headline":"Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient g","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNRUlqcGRmdVRVN3VoT3JVZXhoNEhUckFKNEZ1bXRTOE5FSzFacTdXUkE2cHF4c0xsdjhoNmZzbURtU0xoWWVReHV5c2dfOENhTGN5TU1PQWNOdE5TZWEzQ3RuLUdnZHVocm5GUE9OQ3RpOEJlcmF4dGtmWWk5amtRZmxHeWxwYm1PVnBvd3VXS1NCejFrWEdSb2JKRG83SmlNSmlvNU9YT093Y0NoaUE?oc=5","date":"2025-10-13","type":"regulatory","source":"Fierce Pharma","summary":"FDA adds warning to label of J&J, Legend's Carvykti for potentially fatal intestinal disorder - Fierce Pharma","headline":"FDA adds warning to label of J&J, Legend's Carvykti for potentially fatal intestinal disorder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOTzdCQ254SVJEMzJGejk5YjBkd2hPOGRRcUFNcUlGdzFxcWYzV2NxSXFVYTVRckdGREQ0d1hBUnJ5LVpYOW9ta0RYNFE5dmdpU2VjaWhzRWtxU3lIQmlNdHJJbHZ0RWpJQWpqdlI1X29uN2FibEhEY0dfTUc2RERnRmVRbXpOY2VIdThRaENwdEFUWXU4OGJiVlREZTBTbnBsZmJNWU9IcE5ISXpzNElv?oc=5","date":"2025-10-02","type":"pipeline","source":"Science | AAAS","summary":"New radioactive isotope therapies promise more targeted attacks on cancer - Science | AAAS","headline":"New radioactive isotope therapies promise more targeted attacks on cancer - Science | AAAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQYk82WXJjY0JBdEY4dnRaeUI3eW1MblBOMHJ0aVFEOEE3U3k0dEU4eUo0OWZfVnMxekdfY2RFYzY1bHBxWDFlZGJMZlZRbXpjcUs2cnBVQ242a3ZXUmpXakNLdkRiNFNPenFNS3hZcFU2dDBENTZiWWkybjM3b2xWX0FUcEVJVEFVNFJZMFln?oc=5","date":"2025-09-09","type":"pipeline","source":"Frontiers","summary":"Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody - Frontiers","headline":"Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9rUnFTdVBQMUVMMzBHNk5UWjdyUGg4VHZ2T1B5cjhnV19hOTZpSnFjdEVGQ0tueVZTVlFyS2ItdzhKd3pkVkpKV1VhQXg5cXRKR1N6cVpUSkF2ZldNVEswOWJTQ0FLLXRLX1hZaG130gFyQVVfeXFMTTROU29vVXdteWJIRHMxSV9LUlZ3Z2dKdUdNZy1aNTdzY1Y3YlZPWVZEUW80RGdFQWJGR1YwcmY4SmFHR1dEZjZQbk1qQm1sMkhFcXhmNk5VclIzd3RmQldqUWVNOU9wWnFJUTBhWG4xRnBB?oc=5","date":"2025-08-11","type":"pipeline","source":"koreabiomed.com","summary":"GI Biome changes name to GI Longevity to focus on the anti-aging market - koreabiomed.com","headline":"GI Biome changes name to GI Longevity to focus on the anti-aging market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNM1pOa3IwTUxodktJck4xQTBSY0JWMGx1cmdQTldsSnV5LXROQ1R0MzZ4b2xVUGdXTzQ5YWVvSFdYSmlXOHhacVdfTHlTZGc4My1HYlBLSXZRWW9TdHBuWjgzTm9DU2gyQW5lWUpnN1dfc2RYUEViVWJSUzFPUGx2TGZHbzltZVlHblVMVUhPQWRwSktLSVhJVlBUdTJFTGFJd1pn?oc=5","date":"2025-07-31","type":"deal","source":"DCAT Value Chain Insights","summary":"Bio/Pharma Industry Radar: Top Mergers & Acquisitions Thus Far in 2025 - DCAT Value Chain Insights","headline":"Bio/Pharma Industry Radar: Top Mergers & Acquisitions Thus Far in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9IRnVtdUJ6TEpzUl9pcEFoVGozelRxa3JrWlNoWmtKWWdxdHBpbTI5VVRNQ1FPYkZvWlJYX0YxUzN2ekcwbENoZUpnUEJMWHBrblI1SVZ5M2pfNFJTSURiZkdFUGUwS1NiNWdGR1V3?oc=5","date":"2022-12-27","type":"regulatory","source":"KED Global","summary":"GI Cell wins approval for human cell management from Korean regulator - KED Global","headline":"GI Cell wins approval for human cell management from Korean regulator","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}